CMN Weekly (16 August 2024) - Your Weekly CRISPR...
CMN Weekly
Aug. 16, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
TG Therapeutics
Company Type: Therapeutic development
Main focus: Developing novel therapeutics for B-cell related diseases including autoimmune diseases
Company stage: Clinical
Diseases: B-cell related autoimmune diseases including multiple sclerosis
Genome-editing tool: Meganucleases
Funding stage: Post-IPO Debt
Location: New York City, New York, USA
Website: https://www.tgtherapeutics.com/
Pipeline: https://www.tgtherapeutics.com/our-pipeline/overview-pipeline/
Partners: Precision BioSciences
TG Therapeutics is a biopharmaceutical company focused on developing novel treatments for B-cell diseases, including various forms of cancer and autoimmune diseases. Their primary disease focus is on autoimmune diseases, especially multiple sclerosis (MS). The company's pipeline includes Phase 3 and approved monoclonal antibody treatments for MS, as well as an investigational trial for MS with Azer-Cel, a clinical-stage therapeutic candidate comprising gene-edited donor-derived T cells.
